Tonix Pharmaceuticals (TNXP)
NASDAQ:TNXP
Want to see TNXP full AI Analyst Report?
TNXP Stock Chart & Stats
$15.08
-$0.02(-7.15%)
At close: 4:00 PM EST
$15.08
-$0.02(-7.15%)
Day’s Range― - ―
52-Week Range$11.60 - $69.97
Previous CloseN/A
Volume36.66M
Average Volume (3M)446.90K
Market Cap
$192.23M
Enterprise Value-$18.92M
Total Cash (Recent Filing)$207.64M
Total Debt (Recent Filing)$1.31M
Price to Earnings (P/E)―
Beta1.41
Next Earnings
May 11, 2026EPS Estimate
-2.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.98
Shares Outstanding13,405,401
10 Day Avg. Volume413,261
30 Day Avg. Volume446,900
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.54
Price to Sales (P/S)10.14
P/FCF Ratio-1.29
Enterprise Value/Market Cap-0.10
Enterprise Value/Revenue-1.44
Enterprise Value/Gross Profit-2.93
Enterprise Value/Ebitda0.15
Forecast
1Y Price Target
$51.00Price Target Upside238.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-9.28
Revenue Forecast (FY)$89.70M
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet, Low LeverageA materially stronger capital base and very low debt improve Tonix's financial flexibility to fund clinical programs and absorb trial setbacks without immediate insolvency risk. This reduces near-term refinancing urgency and interest burden, supporting multi-quarter development timelines and strategic optionality.
Positive Phase 3 TONMYA Fibromyalgia DataRobust Phase 3 outcomes with early, sustained pain reductions and a favorable NNT/NNH profile strengthen the commercial and regulatory case for TONMYA. Durable clinical evidence increases likelihood of labelable benefit, partner interest, and a potential first-product revenue stream if approvals and launch succeed.
Uplisting To Nasdaq Global Select MarketListing on Nasdaq's highest tier signals improved governance compliance and may broaden institutional investor access. That structural change can materially ease future capital raises, partnerships, and corporate credibility — important for funding multi-year clinical development programs.
Bears Say
Large, Persistent Negative Cash FlowConsistently large negative operating and free cash flows indicate the company burns meaningful cash each year to fund R&D and operations. This structural cash deficit creates recurring dependence on external financing, heightens dilution risk, and could force program prioritization or delays if capital access tightens.
Deep Operating Losses And Negative MarginsExtreme negative margins reflect a cost base far exceeding current revenue; unless clinical successes convert into material product sales or licensing deals, profitability is unlikely. Sustained operating losses weaken returns and mean scaled commercialization or partnering is required to alter the earnings trajectory.
Clinical-stage Model Dependent On External FundingAs a clinical-stage biotech without established product revenue, Tonix must routinely secure financing or partners to advance trials. This business model creates ongoing capital and execution risk, exposes shareholders to dilution, and makes program continuity contingent on successful fundraises or licensing agreements.
Tonix Pharma News
TNXP FAQ
What was Tonix Pharmaceuticals’s price range in the past 12 months?
Tonix Pharmaceuticals lowest stock price was $11.60 and its highest was $69.97 in the past 12 months.
What is Tonix Pharmaceuticals’s market cap?
Tonix Pharmaceuticals’s market cap is $192.23M.
When is Tonix Pharmaceuticals’s upcoming earnings report date?
Tonix Pharmaceuticals’s upcoming earnings report date is May 11, 2026 which is in 23 days.
How were Tonix Pharmaceuticals’s earnings last quarter?
Tonix Pharmaceuticals released its earnings results on Mar 12, 2026. The company reported -$3.98 earnings per share for the quarter, missing the consensus estimate of -$3.19 by -$0.79.
Is Tonix Pharmaceuticals overvalued?
According to Wall Street analysts Tonix Pharmaceuticals’s price is currently Undervalued.
Does Tonix Pharmaceuticals pay dividends?
Tonix Pharmaceuticals does not currently pay dividends.
What is Tonix Pharmaceuticals’s EPS estimate?
Tonix Pharmaceuticals’s EPS estimate is -2.37.
How many shares outstanding does Tonix Pharmaceuticals have?
Tonix Pharmaceuticals has 13,405,401 shares outstanding.
What happened to Tonix Pharmaceuticals’s price movement after its last earnings report?
Tonix Pharmaceuticals reported an EPS of -$3.98 in its last earnings report, missing expectations of -$3.19. Following the earnings report the stock price went down -1.268%.
Which hedge fund is a major shareholder of Tonix Pharmaceuticals?
Currently, no hedge funds are holding shares in TNXP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tonix Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$51.00 (238.20% Upside)
$51.00 (238.20% Upside)
Blogger Sentiment
Bullish
TNXP Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $286.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.90%
12-Months-Change
Fundamentals
Return on Equity
-60.15%
Trailing 12-Months
Asset Growth
70.16%
Trailing 12-Months
Company Description
Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.
TNXP Stock 12 Month Forecast
Average Price Target
$51.00
▲(238.20% Upside)
Technical Analysis
Ownership Overview
0.18% Insiders
6.71% Mutual Funds
0.02% Other Institutional Investors
84.81% Public Companies and
Individual Investors